Q: Another of your holdings is New York-listed, Israeli company Taro Pharmaceuticals. How does this fit into an India fund?
A: Taro Pharma (TARO) is an Israeli company, but it’s owned by India’s Sun Pharma ceuticals. Sun is one of the most popular companies in India in healthcare. We feel that Sun Pharma is very expensive and 40% to 50% of its profits come from Taro. If you strip the profit and market cap from Pharma, the price-to-earnings multiple you get for Sun Pharma is like 70 or 80 times.
It’s mostly into dermatology and it’s focused on the U.S. and Canada. There’s not much broker coverage - just one or two analysts. That’s one of the reasons the stock’s been much cheaper than other pharma companies listed in India.
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 4,338 NYSE Stocks Price Analysis This stock mode of correlation coefficient is 0.8 In other words, the correlation coefficient of the other stocks
A break of 117.84 could move it up to 139.96 in short term. The buy rating at 9trading is set to 5.
TARO has just seen the last of the selling. Looks like a potential push higher with a EPS % past 5 Y of 25.00%. have you guys heard of awesomesto-cks. i started receiving their allerts and so far i am happy.
Drop in Short Interest: short interest has dropped 208,500 shares as of Feb 28 and is now dow to 2,460,100. For reference, total volume from Feb 16 to Feb 28 was 741,100 shares so short active represents around 28% of the trading activity for that period. Quite surprised shares are not trading higher. Short interest has not been this low since Aug 15, 2016 when amount was 2.44 mm shares. However, shares outstanding back then were higher prior to some of the buyback activity.
Novexatin Update: further significant value creation ahead in the next 12 to 18 Months
Novexatin developer Novabiotics taking in a new cash injection from existing investor Woodford Investment Management representing a “significant uplift” in the company’s valuation.
The investment will be used to fund further trials in the US of its potential “blockbuster” – a brush-on anti-fungal treatment called Novexatin, which is subject to an exclusive licence and co-development agreement with US healthcare firm, Taro Pharmaceuticals.
“Because we have got some data read outs over the next 12-18 months that is going to substantially change the valuation again,” said Mr Foulger.
Novabiotics raises a further £3million and looks to Trump-fueled M&A opportunities | Press and Journal
A leading light of the north-east’s fledgling biotech sector has raised £3million from investors as it considers a trade sale inspired by President Donald Trump’s proposed changes to the US healthcare market. Aberdeen-based Novabiotics has raised the
Who says TARO isn't poised for potentially massive upward movement? How can it with EPS estimate for next year sitting at 10.04? Ive been struggling with this stock lately. Some of my other trades have been from awesom-eSTOCKS which are working out pretty well.
...any news? how is the $250m share repurchase doing? when will be finished where can the stock price go?
Got a great report from http://monstatrader.com/?s=TARO about $TARO. I did have to subscribe but it was worth the time. Thank you guys for the tip! Day trading making money. Developed after years of intensive research.(it was discovered by accident.)
MonstaTrader: OTC, NYSE, NASDAQ Stock Alerts for all Traders
Stock alerts, stock trading, making money, sharing knowledge and always looking for the next big money maker.
...ACADIAN sold 305k shares...any comment?
RDHL (MC $150M) $70+M Cash ..3 BLOCKBUSTER Drugs with P3 results in 1H 2017
RDHL is a brutally undervalued and almost unknown gem with many News coming within 6-7 months including Phase 3 Results from 2 Potential Blockbusters and NDA resubmission in early 2017 . Market Cap of around $150 Million and $60+ Million in cash makes this Biotech one of the most attractive in the Sector . This low float Stock is a gift below $10 with good News we could see $50 easily by end of next year .
Market Cap :$148 Million Cash: $62 Million Price: 9.70
Shares out 15 Million (50% of Shares held by Insiders alone)
Commercial asset: •Potential acquisition of certain commercial rights to GI asset currently on the market in the U.S.
1H 2017 :
RIZAPORT®(RHB-103): •Re-submission of U.S. NDA
RHB-104: [B]•Second DSMB meeting for the MAP US Phase III study for Crohn’s disease, including safety and interim efficacy analysis, with evaluation of option of early stop for success for overwhelming efficacy -Q2/2017 <<<<<<<< POTENTIAL BLOCKBUSTER ..GLOBAL MARKET SIZE : $5+ BILLION
BEKINDA®(RHB-102): •Top-line Phase III results (gastroenteritis) -mid-2017 <<<< MARKET SIZE $650+ MILLION •Top-line Phase II results (IBS-D) -mid-2017
RHB-105 (H. pylori): First Phase III study successfully met its primary endpoint with high statistical significance (p<0.001), confirmatory Phase III planned to be initiated H1/2017 <<<< POTENTIAL BLOCKBUSTER ..GLOBAL MARKET SIZE : $4+ Billion
URGENT HELP NEEDED _ PROXY VOTE I just confirmed, they have sent ONLY VIA POSTAL MAIL (despite my set preference to receive only ONLINE). Since I am traveling, I cannot vote by mail by 12/28. Is there any solution ? I have also sent this to my brokerage asking I need to VOTE ONLINE ONLY. Anybody any help ?
For the recent Taro proxy can anyone help me answer this question ? Proposal 1A states - The undersigned does not have a conflict of interest (a "personal interest" under the Companies Law, as described in the Proxy Statement) (hereinafter, a "conflict of Interest") in the approval of Proposal 1.
The options are YES and NO.
I do not have a conflict of interest under companies law and I want the company to know that. What should I answer ? Please let me know .
Chutzpah 1 – Billionaire Dilip wants me to pay him more than $1.7M ( all together) for “managing” Taro’s share down from $170 to ~$100. This guy and his gang have no shame? Chutzpa 2 and irony 1 – if Taro is found guilty in price fixing, Taro’s share will plummet, and Sun stands to benefit.